March 10, 2020 / 7:43 PM / in 20 days

BRIEF-Treatment With Gilead’s Vesatolimod Is Evaluated For Safety And Virologic And Immunologic Response Versus Placebo In Phase 1B Hiv Functional Cure Study

March 10 (Reuters) - Gilead Sciences Inc:

* TREATMENT WITH GILEAD’S VESATOLIMOD IS EVALUATED FOR SAFETY AND VIROLOGIC AND IMMUNOLOGIC RESPONSE VERSUS PLACEBO IN PHASE 1B HIV FUNCTIONAL CURE STUDY

* GILEAD - RESULTS SUPPORT FURTHER EVALUATION OF VESATOLIMOD AS PART OF INVESTIGATIONAL CURATIVE REGIMENS AIMED AT ACHIEVING ART-FREE HIV CONTROL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below